Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor

Citation
C. Bousquet et al., Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor, J CLIN INV, 104(9), 1999, pp. 1277-1285
Citations number
36
Categorie Soggetti
Medical Research General Topics
Journal title
JOURNAL OF CLINICAL INVESTIGATION
ISSN journal
00219738 → ACNP
Volume
104
Issue
9
Year of publication
1999
Pages
1277 - 1285
Database
ISI
SICI code
0021-9738(199911)104:9<1277:IRFSAS>2.0.ZU;2-E
Abstract
Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. W e show here that LIF-induced JAK2 and STAT3 tyrosine phosphorylation is tra nsient, disappearing within 20 and 40 minutes, respectively. LIF activates the SH2 domain-containing tyrosine phosphatase, SHP-1, with maximal stimula tion observed at 30 minutes. SHP-1 is constitutively associated with JAK2, and LIF induces recruitment of phosphorylated STAT3 to this complex. Overex pression of wild-type or dominant negative forms of SHP-1 shows decreased o r increased LIF-induced proopiomelanocortin (POMC) promoter activity, respe ctively. LIF-induced JAK2 and STAT3 dephosphorylation is delayed until afte r 60 minutes in cells that overexpress the mutant SHP-1. In addition, SOCS- 3, a negative regulator of LIF signaling, binds to JAK2 after 60 minutes of LIF stimulation, after which the complex is degraded by the proteasome. SO CS-3 overexpression blocks LIF-induced JAK2 tyrosine phosphorylation, confi rming a role for SOCS-3 in deactivating JAK2 by direct association. Using S OCS-3 fusion proteins, we also define regions of the SOCS-3 protein that ar e critical for inhibition of LIF-induced POMC promoter activity. Corticotro phic signaling by LIF is thus subject to 2 forms of negative autoregulation : dephosphorylation of JAK2 and STAT3 by the SHP-1 tyrosine phosphatase, an d SOCS-3-dependent inactivation of JAK2.